Scarica l'app Stockscreener
2.53
0.80%
0.02
Dopo l'orario di chiusura:
2.53
Precedente Chiudi:
$2.51
Aprire:
$2.5098
Volume 24 ore:
15,240
Relative Volume:
0.85
Capitalizzazione di mercato:
$72.41M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-2.32%
1M Prestazione:
-7.33%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$2.33
$2.59
Intervallo di 1 settimana:
$2.33
$2.66
Portata 52W:
$2.33
$3.09
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Nome
Insight Molecular Diagnostics Inc
Settore
Industria
Telefono
949-409-7600
Indirizzo
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Confronta IMDX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
2.53 | 71.84M | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
492.72 | 184.93B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
205.82 | 147.00B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
647.09 | 51.77B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
125.66 | 35.50B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
190.81 | 32.08B | 15.70B | 1.24B | 2.01B | 6.91 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-28 | Iniziato | Lake Street | Buy |
| 2022-05-24 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-03-17 | Ripresa | Needham | Buy |
| 2021-01-07 | Aggiornamento | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | Iniziato | BTIG Research | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | Reiterato | The Benchmark Company | Speculative Buy |
| 2020-07-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | Iniziato | Needham | Buy |
| 2019-02-13 | Iniziato | Piper Jaffray | Overweight |
| 2019-01-29 | Aggiornamento | Janney | Neutral → Buy |
| 2018-12-19 | Ripresa | Lake Street | Buy |
Mostra tutto
Insight Molecular Diagnostics Inc Borsa (IMDX) Ultime notizie
iMDx to Participate in NYC Investment Conferences September 811 - GlobeNewswire
iMDx Announces Participation in NYC Investment Conferences - AInvest
Molecular Diagnostics Leader iMDx Announces Double-Header NYC Investor Conference Schedule for September - Stock Titan
iMDx CFO Andrea James discusses democratizing molecular diagnostics in podcast episode. - AInvest
IMDX CFO Andrea James Featured in Empowered Patient Podcast on Democratizing Molecular Diagnostics - MarketScreener
HIV Diagnostics Market Size, Share & Forecast, 2025–2034 - Global Market Insights Inc.
Insight Molecular Diagnostics: Pioneering the Next Generation of Transplant Rejection Testing and FDA Readiness - AInvest
Veterinary Molecular Diagnostics Market on Track for Massive Expansion by 2035, Forecasts Reveal. - newstrail.com
Analysts Offer Insights on Healthcare Companies: Immatics (IMTX) and Insight Molecular Diagnostics (IMDX) - The Globe and Mail
Insight Molecular Diagnostics Inc. shares rise 12.92% intraday after Myriad Genetics appoints new CFO. - AInvest
Molecular Diagnostics Market Evolving Rapidly from 2025 to 2032 | F. Hoffmann-La Roche Ltd, Illumina, Inc. - openPR.com
Insight Molecular: Needham Reiterates Buy Rating with $4.25 PT - AInvest
Insight Molecular Diagnostics: Paving the Next Frontier in Transplant Rejection Testing with FDA-Ready Innovation - AInvest
IMDX’s GraftAssureDx Study: A Game-Changer in Kidney Transplant Monitoring? - TipRanks
Insight Molecular Diagnostics Inc. shares rise 1.21% intraday after Caris Life Sciences validates MI Cancer Seek® assay. - AInvest
Insight Molecular Diagnostics Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st
Insight Molecular Diagnostics : With Q&A (insight molecular diagnostics inc imdx us q2 2025 earnings call 11 august 2025 5 00 pm et) - MarketScreener
Lake Street Sticks to Their Buy Rating for Insight Molecular Diagnostics (IMDX) - The Globe and Mail
Insight Molecular Diagnostics Inc. shares fall 1.53% intraday after reporting a Q2 loss of $9.7 million. - AInvest
Insight Molecular Diagnostics Inc (IMDX) Q2 2025 Earnings Call Highlights: Strategic Advances ... - Yahoo Finance
Needham reiterates Buy rating on Insight Molecular Diagnostics stock By Investing.com - Investing.com Nigeria
Needham reiterates Buy rating on Insight Molecular Diagnostics stock - Investing.com India
Insight Molecular Diagnostics: Promising Future with GraftAssureIQ and Strategic Expansion - TipRanks
Insight Molecular Diagnostics: Q2 Earnings Snapshot - Connecticut Post
Insight Molecular Diagnostics Reports Q2 2025 Progress - TipRanks
IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch - Santé log
Earnings call transcript: Insight Molecular Diagnostics Q2 2025 reveals strategic advancements - Investing.com Canada
Insight Molecular Diagnostics Reports Q2 Loss of $9.7 Million - AInvest
IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx L - GuruFocus
IMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference - 富途牛牛
Insight Molecular Diagnostics Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Insight Molecular Diagnostics Inc.Common Stock (Nasdaq:IMDX) Stock Quote - FinancialContent
Molecular Diagnostics Market Overview: Growth Factors to 2035 - MarketReports.us
PCR Molecular Diagnostics Market Global Forecast 2025–2032: Sector-Wise Insights - newstrail.com
Insight Molecular Diagnostics Inc. shares rise 8.81% premarket after QIAGEN's solid Q2 2025 results. - AInvest
iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference - The Manila Times
iMDx to Release Second Quarter 2025 Results on August 11, - GlobeNewswire
iMDx Announces Two Major Investor Events: Q2 Earnings and Needham Conference Back-to-Back - Stock Titan
Diagnostic Contract Manufacturing Market Forecast 2025–2034: Key Metrics and Strategic Insights - WhaTech
IMDX World Transplant Congress Late-Breaking Data - GlobeNewswire
Revolutionary Transplant Test Achieves 79% Accuracy, Nearly Doubles Industry Standard in Detecting Organ Rejection - Stock Titan
U.S., Europe, and Asia Pacific Molecular Diagnostics Market - openPR.com
iMDx to Host Virtual KOL Event to Discuss its In-House - GlobeNewswire
Vanderbilt Professor Reveals Game-Changing In-House Kidney Transplant Testing Technology at Expert Event - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: ProMIS Neurosciences (PMN), Bruker (BRKR) - The Globe and Mail
Insight Molecular Diagnostics Inc. shares fall 3.16% intraday as ImmunoPrecise Antibodies Ltd. announces new findings. - AInvest
Insight Molecular Diagnostics Inc. shares rise 5.32% premarket after Seegene unveils new diagnostic system and data analytics platform. - AInvest
Insight Molecular Diagnostics Insiders Increase Holdings Amidst Bullish Bets - AInvest
Insight Molecular Diagnostics Inc Azioni (IMDX) Dati Finanziari
Non sono disponibili dati finanziari per Insight Molecular Diagnostics Inc (IMDX). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):